CNR2 and neoplasm: To address the role of CB2-expressing KP cells on tumor growth in situ, we pharmacologically activated or blocked CB2 in tumor-bearing CB2-/- mice using a CB2 agonist (JWH133) (Figure 4C) or CB2 antagonist (SR144528) (Figure 4E) at previously published doses (29, 31).